ProQR Therapeutics (NASDAQ:PRQR) Issues Earnings Results, Meets Estimates

ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10), Zacks reports. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%.

ProQR Therapeutics Stock Performance

Shares of NASDAQ:PRQR opened at $1.74 on Friday. The firm has a market cap of $142.12 million, a PE ratio of -5.44 and a beta of 0.24. The firm’s fifty day moving average is $2.27 and its 200-day moving average is $2.62. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PRQR. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Monday. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $9.17.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).